Cipla, Sandoz Gearing For Seretide Challenge In Australia?

The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.

More from Business

More from Scrip